BMJ Paediatrics Open (Dec 2019)

Gabapentin for the treatment of pain manifestations in children with severe neurological impairment: a single-centre retrospective review

  • Seamus Hussey,
  • Billy Bourke,
  • Annemarie Broderick,
  • Mary Devins,
  • Rory Mannion,
  • Aedin Collins

DOI
https://doi.org/10.1136/bmjpo-2019-000467
Journal volume & issue
Vol. 3, no. 1

Abstract

Read online

Pain, irritability and feeding intolerance are common symptoms affecting quality of life in children with severe neurological impairment (SNI). We performed a retrospective study to explore the use of gabapentinoid medications for symptom control in children with SNI. Patients attending the palliative care or gastroenterology department being treated with gabapentin for irritability, vomiting or pain of unknown origin were included. Information was gathered retrospectively from medical documentation. Irritability was reduced in 30 of the 42 patients included. Gabapentin was discontinued in 15 children, 12 of whom then received pregabalin. Three children had a good response to pregabalin, six a minimal improvement and three no improvement. These results support the use of gabapentinoids in this patient cohort.